# MiMedx Group Inc (MDXG) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $3.25, market value $474 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). MiMedx Group Inc reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 2.13**. A PEG of 2.13 means the P/E is high relative to expected earnings growth; the price already assumes a lot.
- **Price / sales: 1.6×**. Each dollar of revenue is priced at 1.6×.
- **Price / book: 2.2×**. The shares trade at 2.2× book value; book value is a meaningful part of the valuation.

## Profitability
- **Gross margin: 77.3%**. MiMedx Group Inc keeps 77.3% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -8.3%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: 11.6%**. 11.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 18.9%**. 18.9% on shareholders' equity is solid.
- **Return on invested capital: -18.3%**. Return on all capital, debt included, is -18.3%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -5.6%**. Each dollar of assets produces -5.6% of profit.

## Growth
- **Revenue growth (1 yr): 20.0%** (3-yr 16.1%/yr, 5-yr 11.0%/yr). Revenue grew 20.0% over the last year, against 11.0% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 14.3%**. Earnings per share rose 14.3%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.07**. Debt is 0.07 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 6.7×**. It would take 6.7 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Current ratio: 4.32** (quick 4.32). Current assets cover the next year's liabilities 4.32 times.
- **Altman Z-score: 6.94**. A Z-score of 6.94 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. MiMedx Group Inc does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover MiMedx Group Inc; the consensus is strong_buy, with an average price target of $7.00 (+115% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -57.1%** (YTD -51.6%, 3-mo -23.2%). The shares are down 57.1% over twelve months including dividends.
- **From 52-week high: -59.2%** (7.3% above the low). Trading 59% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 22**. An RSI of 22 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 0.84** (volatility 44%). Beta of 0.84 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MDXG · Page: https://foliofundamentals.com/stocks/mdxg

Not investment advice.